BidaskClub upgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from a sell rating to a hold rating in a report published on Tuesday morning.
A number of other research analysts have also weighed in on AIMT. Zacks Investment Research raised Aimmune Therapeutics from a sell rating to a hold rating in a research note on Tuesday, July 24th. Credit Suisse Group set a $40.00 price target on Aimmune Therapeutics and gave the stock a buy rating in a research note on Monday, August 13th. ValuEngine lowered Aimmune Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, September 7th. Stifel Nicolaus initiated coverage on Aimmune Therapeutics in a research report on Thursday, September 13th. They issued a hold rating and a $33.00 target price on the stock. Finally, Roth Capital set a $80.00 target price on Aimmune Therapeutics and gave the stock a buy rating in a research report on Tuesday, October 9th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $50.70.
Shares of Aimmune Therapeutics stock opened at $27.29 on Tuesday. Aimmune Therapeutics has a fifty-two week low of $24.56 and a fifty-two week high of $42.00. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -10.46 and a beta of -0.27.
Several institutional investors and hedge funds have recently modified their holdings of AIMT. Point72 Asset Management L.P. raised its position in shares of Aimmune Therapeutics by 56.4% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,688,783 shares of the biotechnology company’s stock worth $45,411,000 after buying an additional 608,883 shares during the period. BlackRock Inc. raised its position in shares of Aimmune Therapeutics by 18.4% in the 2nd quarter. BlackRock Inc. now owns 3,643,840 shares of the biotechnology company’s stock worth $97,984,000 after buying an additional 565,410 shares during the period. C WorldWide Group Holding A S raised its position in shares of Aimmune Therapeutics by 100.1% in the 2nd quarter. C WorldWide Group Holding A S now owns 246,749 shares of the biotechnology company’s stock worth $6,635,000 after buying an additional 123,466 shares during the period. Northern Trust Corp increased its holdings in Aimmune Therapeutics by 26.3% in the 2nd quarter. Northern Trust Corp now owns 518,581 shares of the biotechnology company’s stock valued at $13,945,000 after purchasing an additional 108,034 shares in the last quarter. Finally, Fiera Capital Corp acquired a new stake in Aimmune Therapeutics in the 2nd quarter valued at $2,492,000. 78.14% of the stock is currently owned by institutional investors and hedge funds.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
Read More: Short Selling Stocks and Day Traders
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.